Role of MR-proADM and Monocyte CD169 in Predicting In-Hospital and 60-Day Mortality in COVID-19 Patients.

IF 1.9 Q3 PATHOLOGY

Clinical Pathology Pub Date : 2024-12-16 eCollection Date: 2024-01-01 DOI:10.1177/2632010X241304958

Sergio Venturini, Daniele Orso, Francesco Cugini, Giovanni Del Fabro, Astrid Callegari, Ingrid Reffo, Danilo Villalta, Laura de Santi, Elisa Pontoni, Dina Giordani, Paolo Doretto, Chiara Pratesi, Maurizio Tonizzo, Gian Luca Colussi, Massimo Crapis

{"title":"Role of MR-proADM and Monocyte CD169 in Predicting In-Hospital and 60-Day Mortality in COVID-19 Patients.","authors":"Sergio Venturini, Daniele Orso, Francesco Cugini, Giovanni Del Fabro, Astrid Callegari, Ingrid Reffo, Danilo Villalta, Laura de Santi, Elisa Pontoni, Dina Giordani, Paolo Doretto, Chiara Pratesi, Maurizio Tonizzo, Gian Luca Colussi, Massimo Crapis","doi":"10.1177/2632010X241304958","DOIUrl":null,"url":null,"abstract":"Objectives: Mid-regional pro-adrenomedullin (MR-proADM) and monocyte CD169 (CD169) are valuable prognostic indicators of severe COVID-19.Methods: We assessed the predictive ability of a single measurement of MR-proADM and CD169 at emergency department (ED) admission to forecast in-hospital and 60-day mortality in adult COVID-19 patients. We analyzed clinical and laboratory data, with in-hospital mortality as the primary endpoint and 60-day mortality as the secondary endpoint. We examined associations with clinical and laboratory variables through univariate and multivariate analyses.Results: Data from 382 patients over 14 months were analyzed. Significant predictors of in-hospital mortality included age ⩾ 70 years (hazard ratio [HR] 8.1; 95% confidence interval [CI] 2.2-29.5), CD169 ratio ⩾ 20 (HR: 2.4; 95%CI: 1.6-5.6), MR-proADM ⩾ 1.1 mmol/L (HR: 5.1; 95%CI: 1.7-15.6), the need for invasive mechanical ventilation (HR: 6.8; 95%CI: 2.4-19.1), and active cancer (HR: 5.2; 95%CI: 1.8-15.2). For 60-day mortality, only elevated MR-proADM levels showed predictive value (HR: 6.7; 95%CI: 1.7-25.0), while high serologic titer was protective (HR: 0.4; 95%CI: 0.1-0.9).Conclusion: A single MR-proADM and CD169 measurement upon ED admission has prognostic value for in-hospital mortality, with MR-proADM also predicting 60-day mortality.","PeriodicalId":53204,"journal":{"name":"Clinical Pathology","volume":"17 ","pages":"2632010X241304958"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650471/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2632010X241304958","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Mid-regional pro-adrenomedullin (MR-proADM) and monocyte CD169 (CD169) are valuable prognostic indicators of severe COVID-19.

Methods: We assessed the predictive ability of a single measurement of MR-proADM and CD169 at emergency department (ED) admission to forecast in-hospital and 60-day mortality in adult COVID-19 patients. We analyzed clinical and laboratory data, with in-hospital mortality as the primary endpoint and 60-day mortality as the secondary endpoint. We examined associations with clinical and laboratory variables through univariate and multivariate analyses.

Results: Data from 382 patients over 14 months were analyzed. Significant predictors of in-hospital mortality included age ⩾ 70 years (hazard ratio [HR] 8.1; 95% confidence interval [CI] 2.2-29.5), CD169 ratio ⩾ 20 (HR: 2.4; 95%CI: 1.6-5.6), MR-proADM ⩾ 1.1 mmol/L (HR: 5.1; 95%CI: 1.7-15.6), the need for invasive mechanical ventilation (HR: 6.8; 95%CI: 2.4-19.1), and active cancer (HR: 5.2; 95%CI: 1.8-15.2). For 60-day mortality, only elevated MR-proADM levels showed predictive value (HR: 6.7; 95%CI: 1.7-25.0), while high serologic titer was protective (HR: 0.4; 95%CI: 0.1-0.9).

Conclusion: A single MR-proADM and CD169 measurement upon ED admission has prognostic value for in-hospital mortality, with MR-proADM also predicting 60-day mortality.

查看原文本刊更多论文

MR-proADM和单核细胞CD169在预测COVID-19患者住院和60天死亡率中的作用

目的：中区域肾上腺素原（MR-proADM）和单核细胞CD169 （CD169）是预测重症COVID-19患者预后的重要指标。方法：我们评估了急诊（ED）入院时MR-proADM和CD169的单一测量对预测成人COVID-19患者住院和60天死亡率的预测能力。我们分析了临床和实验室数据，以住院死亡率为主要终点，60天死亡率为次要终点。我们通过单变量和多变量分析检查了与临床和实验室变量的关联。结果：对382例患者14个月的数据进行了分析。住院死亡率的重要预测因素包括年龄大于或等于70岁(风险比[HR] 8.1；95%置信区间[CI] 2.2-29.5)， CD169比值大于或等于20 (HR: 2.4；95%置信区间:1.6—-5.6),MR-proADM⩾1.1更易/ L(人力资源:5.1;95%CI: 1.7-15.6)，需要有创机械通气(HR: 6.8；95%CI: 2.4-19.1)和活动性癌症(HR: 5.2；95%置信区间:1.8—-15.2)。对于60天死亡率，只有MR-proADM水平升高具有预测价值(HR: 6.7；95%CI: 1.7-25.0)，而高血清学滴度具有保护作用(HR: 0.4；95%置信区间:0.1—-0.9)。结论：ED入院时单次MR-proADM和CD169检测对住院死亡率具有预测价值，MR-proADM还可预测60天死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Pathology PATHOLOGY-

CiteScore

2.20

自引率

7.70%

发文量